Findings

What do systematic reviews say?

9 questions · 9 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 55.6%GRADE not reported 0 · 0%Very low 4 · 44.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ursodeoxycholic acid vs placebo or no intervention

Serious adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.87 [0.68, 1.12]
14 studies · 1382 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

Non‐serious adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 1.46 [0.83, 2.56]
12 studies · 1277 participants
Very low

Ursodeoxycholic acid vs placebo

Serious adverse events · people with primary sclerosing cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary sclerosing cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ursodeoxycholic acid vs no intervention

Serious adverse events (proportion) · people with primary biliary cholangitis

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 380 participants
Very low

Ursodeoxycholic acid vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (proportion) · people with primary biliary cholangitis

It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
OR 3.08 [0.12, 78.14]
1 study · 74 participants
Very low

Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (proportion) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found